Pemphigus vulgaris
What Is Pemphigus Vulgaris?
Pemphigus vulgaris is an autoimmune disease that causes blistering of the skin and mucous membranes, characterized by a process called acantholysis, in which skin cells lose their normal attachment to one another.1
The condition is the most frequent and most severe form of pemphigus, occurring across all populations, most commonly between the ages of forty and sixty.1
Pemphigus vulgaris is caused by autoantibodies that target desmoglein one and desmoglein three, proteins that form part of the specialized structures responsible for holding skin cells firmly together.2
Pemphigus vulgaris is caused by autoantibodies that target desmoglein 1 and desmoglein 3, which are components of desmosomes responsible for keratinocyte intercellular adhesions.
National Center for Biotechnology Information
Symptoms
Patients with pemphigus vulgaris typically present with blisters on the skin along with painful erosions affecting the mucous membranes, including the inside of the mouth.1
In the mucosal dominant form of the disease, antibodies against desmoglein three are the primary driver, while desmoglein one becomes an additional antibody target when the skin itself becomes involved.2
The binding of these autoantibodies to cell to cell junctions results in breakdown of normal cellular adhesion, directly causing the characteristic blistering and erosion seen in affected patients.2
Causes
Desmogleins are specialized proteins that form an essential part of desmosomes, structures required for proper cell to cell adhesion within the skin’s outer layers.2
When autoantibodies bind to these desmoglein proteins, the resulting disruption breaks down normal cellular connections, causing skin cells to separate from one another in a process known as acantholysis.1
This loss of normal cellular adhesion occurs independently of certain other cellular growth pathways, indicating a relatively direct and specific mechanism of tissue damage driven by the autoantibodies themselves.3
Risk Factors
Age between forty and sixty years represents the most typical demographic for pemphigus vulgaris onset, though the condition can occur in patients both younger and older than this typical range.1
Age of onset sixty five years or older, along with the presence of coronary heart disease at the time of diagnosis, have both been identified as independent risk factors associated with increased overall mortality.4
A history of diabetes mellitus and shorter disease duration prior to starting rituximab treatment have both been associated with a shorter time to disease relapse following initial treatment.5
Complications
Widespread skin and mucosal blistering can lead to serious, potentially fatal complications including malnutrition, dehydration, and sepsis if left inadequately treated.5
Additional risk factors for disease relapse include a high percentage of body surface area affected by pemphigus involvement, elevated body mass index, high disease severity at initial onset, and delayed treatment initiation.5
Elevated antibody levels against desmoglein one and desmoglein three following treatment have also been associated with a higher likelihood of disease relapse over time.5
Treatment
Treatment is typically performed using systemic corticosteroids, often combined with additional immunosuppressive medications such as azathioprine or mycophenolate mofetil.1
Rituximab has become approved as a first line treatment for pemphigus vulgaris, effectively inducing remission in a substantial proportion of treated patients.4
In clinical studies, fifty eight percent of patients achieved complete remission on minimal or no additional therapy following rituximab treatment, demonstrating its significant effectiveness as a modern treatment option.4
Prevention
Because pemphigus vulgaris results from an unpredictable autoimmune process, there is no established way to reliably prevent the condition from developing.
Early treatment initiation following diagnosis appears to reduce the risk of subsequent disease relapse, highlighting the importance of prompt medical evaluation of concerning symptoms.5
Ongoing monitoring of desmoglein antibody levels following treatment can help identify patients at higher risk of relapse, supporting more proactive long term management.5
Why Visual Communication Matters for Pemphigus Vulgaris
Explaining how autoantibodies disrupt cellular adhesion structures to produce visible blistering requires visuals that connect microscopic immune activity to the clinical findings patients and clinicians observe directly.
Pharmaceutical companies, dermatology and rheumatology practices, and patient education organizations rely on precise illustration and animation to explain pemphigus vulgaris diagnosis and treatment.
- Illustrating desmosome anatomy and autoantibody targeting
- Animating the process of acantholysis and blister formation
- Explaining the mechanism of action of rituximab and other immunosuppressive therapies
- Visualizing mucosal versus cutaneous disease presentation
- Supporting patient education on relapse risk and treatment monitoring
- Creating training materials for dermatology clinicians
How Biotic Artlab Supports Pemphigus Vulgaris Communication
We work with pharmaceutical companies, dermatology and rheumatology practices, and healthcare organizations to create scientifically accurate visuals that make pemphigus vulgaris easier to understand.
- Custom 3D animations of desmosome biology and autoantibody activity
- Detailed illustrations of blister formation and disease progression
- Mechanism of action animations for rituximab and immunosuppressive therapy
- Patient facing materials on symptom recognition and relapse monitoring
- Clinical training content for dermatology teams
- Conference presentations and marketing visuals for autoimmune skin disease audiences
Frequently Asked Questions
What is pemphigus vulgaris?
It is an autoimmune disease causing blistering of the skin and mucous membranes due to loss of normal cell adhesion.1
What causes pemphigus vulgaris?
Autoantibodies target desmoglein proteins responsible for holding skin cells together, causing them to separate.2
Who is most commonly affected?
The condition most commonly develops between ages forty and sixty, though it can occur at other ages.1
How is pemphigus vulgaris treated?
Treatment typically includes systemic corticosteroids and immunosuppressive medications, with rituximab now used as first line therapy.1
What increases the risk of relapse?
Diabetes, shorter disease duration before treatment, high disease severity, and elevated antibody titers after treatment all increase relapse risk.5
Can pemphigus vulgaris be life threatening?
Yes, widespread blistering can lead to serious complications including malnutrition, dehydration, and sepsis if untreated.5
Have a Project in Mind? Contact Us.
If you are developing patient education materials, clinical training content, or marketing visuals related to pemphigus vulgaris, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.
References
- National Center for Biotechnology Information. Pemphigus Vulgaris.
- National Center for Biotechnology Information. Evaluation of Desmoglein 1 and 3 Autoantibodies in Pemphigus Vulgaris, Correlation With Disease Severity.
- National Center for Biotechnology Information. Pemphigus Vulgaris IgG Cause Loss of Desmoglein-Mediated Adhesion and Keratinocyte Dissociation Independent of Epidermal Growth Factor Receptor.
- National Center for Biotechnology Information. Rituximab in Pemphigus Vulgaris, A Review of Monoclonal Antibody Therapy in Dermatology.
- National Center for Biotechnology Information. Pemphigus Relapse, Mechanisms, Risk Factors, and Agents Associated With Disease Recurrence.
Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, or individualized advice from a qualified healthcare professional.